SMR3B and thyroid gland carcinoma: In conclusion, our experimental results collectively establish SMR3B as a prognostic biomarker in both breast cancer and thyroid cancer, significantly restraining key oncogenic phenotypes including proliferation, migration, and invasion of cancer cells.